Pulse Biosciences, Inc. (PLSE)
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy
Does Pulse Biosciences, Inc (PLSE) have what it takes to be a top stock pick for momentum investors? Let's find out.
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Pulse Biosciences, Inc. (PLSE) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Pulse Biosciences Q1 Earnings Call Highlights
Pulse Biosciences NASDAQ: PLSE said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial fibrillation after reporting first-quarter 2026 results and highlighting new clinical data from its cardiac catheter program.
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
Pulse Biosciences (PLSE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.17 per share a year ago.
Pulse Biosciences, Inc. (PLSE) Shareholder/Analyst Call Transcript
Pulse Biosciences, Inc. (PLSE) Shareholder/Analyst Call Transcript
Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study
PLSE begins patient enrollment in NANOPULSE-AF pivotal study, advancing its NPS tech toward potential AF treatment approval and entry into a large cardiac market.
PLSE Accelerates Cardiac Catheter Program After Breakthrough AFib Data
Pulse Biosciences pivots to its nPulse AFib system after strong clinical results, ramping investment to accelerate development and future commercialization.
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
Pulse Biosciences, Inc. (PLSE) Q4 2025 Earnings Call Transcript
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates
Pulse Biosciences, Inc (PLSE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.17 per share a year ago.
PLSE Shares Positive First-in-Human nPulse Cardiac Catheter Data
Pulse Biosciences shares late-breaking AF data showing up to 100% procedural success, fast procedures and low adverse events for nPulse.
Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pulse Biosciences, Inc. (PLSE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
